Anti-GOR and hepatitis C virus in autoimmune liver diseases

Michel, Gerd; Ritter, A.; Decker, Richard H.; Gerken, Guido; Büschenfelde, K-H Meyer zum; Manns, Michael P.

doi:10.1016/0140-6736(92)91332-3

Cited by 183 publications

(59 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, HCV infection could initiate an autoimmune process through a mechanism of molecular mimicry between epitopes of virus and host. This possibility is suggested by the detection in HCV-positive subjects of anti-GOR antibodies [92][93][94], which are specific for both HCV core and host nuclear antigen [92]. Because GOR is a nuclear antigen detected only in nuclei of cancer cells, in which it is probably overexpressed, it is likely that the GOR gene may well be an oncogene [92].…”

Section: Chronic Hcv Infectionmentioning

confidence: 99%

Viruses and cancers: possible role of hepatitis C virus

Ferri

Civita

Zignego

et al. 1997

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. Oncogenesis is a multifactorial process in which environmental, genetic and infectious factors are variably involved. A possible role of specific viruses has been suggested in at least 15% of human cancers. Hepatitis C virus (HCV), which is both hepato-and lymphotropic, is responsible for various liver disorders, i.e. chronic hepatitis, cirrhosis and hepatocellular carcinoma, as well as for a constellation of extrahepatic immune-mediated manifestations, among which is mixed cryoglobulinaemia. This is a systemic disorder secondary to a chronic, benign B-lymphocyte proliferation, which in some subjects may evolve to a malignant non-Hodgkin's lymphoma (NHL). Interestingly, recent studies reported the appearance of malignant B-cell neoplasias in patients with type C chronic hepatitis; moreover, in a significant number (from 22% to 50%) of 'idiopathic' NHLs, the presence of HCV infection has been demonstrated. The presence of a geographical etherogeneity in the prevalence of HCV-positive NHL suggests that other co-factors, i.e. genetic and environmental, could be involved in the lymphomagenesis. HCV may exert its oncogenic potential in two different directions, leading to liver cancer or B-cell lymphoma.

show abstract

Section: Chronic Hcv Infectionmentioning

confidence: 99%

Viruses and cancers: possible role of hepatitis C virus

Ferri

Civita

Zignego

et al. 1997

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…The finding by Mishiro et al (1990) of non-A, non-B hepatitis-specific antibodies directed at a host-derived epitope (anti-GOR) calls for reclassification of CLD. There appear to be two sub-types of anti-LKM 1 chronic active hepatitis Subtype 2a has high-titer anti-LKMI but neither anti-HCV nor anti-GOR antibodies; subtype 2b has low anti-LKM I titers but high anti-GOR, and is HCV-associated, responds poorly to immunosuppressive therapy, and is seen mainly in older females (Michel et al, 1992 in Italy is type 2b, and less than 10% is this type in England, and thus interpretation of anti-HCV seropositivity depends not only on the test used and the patient's clinical background, but also on geographic and/or genetic factors (Lenzi et al,199 1; Michel et al, 1992).…”

Section: (3) Drugsmentioning

confidence: 99%

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

475

461

View full text Add to dashboard Cite

Lichen planus (LP) is a relatively common disorder of the stratified squamous epithelia, which is, in many ways, an enigma. This paper is the consensus outcome of a workshop held in Switzerland in 1995, involving a selection of clinicians and scientists with an interest in the condition and its management. The oral (OLP) eruptions usually have a distinct clinical morphology and characteristic distribution, but OLP may also present a confusing array of patterns and forms, and other disorders may clinically simulate OLP. Lesions may affect other mucosae and/or skin. Lichen planus is probably of multifactorial origin, sometimes induced by drugs or dental materials, often idiopathic, and with an immunopathogenesis involving T-cells in particular. The etiopathogenesis appears to be complex, with interactions between and among genetic, environmental, and lifestyle factors, but much has now been clarified about the mechanisms involved, and interesting new associations, such as with liver disease, have emerged. The management of lichen planus is still not totally satisfactory, and there is as yet no definitive treatment, but there have been advances in the control of the condition. There is no curative treatment available; immunomodulation, however, can control the condition. Based on the observed increased risk of malignant development, OLP patients should be offered regular follow-up examination from two to four times annually and asked to report any changes in their lesions and/or symptoms. Follow-up may be particularly important in patients with atrophic/ulcerative/erosive affections of the tongue, the gingiva, or the buccal mucosa. Much more research is required into the genetic and environmental aspects of lichen planus, into the premalignant potential, and into the possible associations with chronic liver, and other, disorders. More clinical studies are required into the possible efficacy of immunomodulatory drugs such as pentoxifylline and thalidomide.

show abstract

“…17 Anti-GOR is a common finding in patients with welldocumented chonic HCV infection 9,18 and it has been suggested that anti-GOR may reflect HCV-induced autoimmunity. 9,19 High prevalence of anti-GOR antibodies (p-value < 0.001) were demonstrated in patients of group 1 that exhibited both anti-HCV and antithyroid autoantibodies.…”

Section: Discussionmentioning

confidence: 99%